Source: Journal of rheumatology. Unidade: FM
Subjects: ARTRITE REUMATOIDE JUVENIL, NEUTRÓFILOS, FÁRMACOS ANTIRREUMÁTICOS, INFECÇÕES OPORTUNISTAS
ABNT
PARDEO, Manuela et al. Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis. Journal of rheumatology, v. 46, n. 9, p. 1117-1126, 2019Tradução . . Disponível em: https://doi.org/10.3899/jrheum.180795. Acesso em: 23 maio 2024.APA
Pardeo, M., Wang, J., Ruperto, N., Alexeeva, E., Chasnyk, V., Schneider, R., et al. (2019). Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis. Journal of rheumatology, 46( 9), 1117-1126. doi:10.3899/jrheum.180795NLM
Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz H-I, Minden K, Silva CAA da. Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis [Internet]. Journal of rheumatology. 2019 ; 46( 9): 1117-1126.[citado 2024 maio 23 ] Available from: https://doi.org/10.3899/jrheum.180795Vancouver
Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz H-I, Minden K, Silva CAA da. Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis [Internet]. Journal of rheumatology. 2019 ; 46( 9): 1117-1126.[citado 2024 maio 23 ] Available from: https://doi.org/10.3899/jrheum.180795